Issue 6, 2022

Poly(lactic-co-glycolic acid) encapsulated platinum nanoparticles for cancer treatment

Abstract

Metal nanoparticles have been of interest to the field of nanomedicine due to their potential for cancer treatment, diagnosis, and antimicrobial activity. Particularly, platinum nanoparticles (PtNPs) have been reported to have remarkable anticancer effects and low toxicity in healthy cells. In this paper, we propose a delivery system for PtNPs as a substitute for common chemotherapy treatment. The anticancer effect of PtNPs was tested against triple negative breast cancer (TNBC) showing no cell viability for most of the concentrations used, while not being toxic against fibroblasts. To improve accumulation at the tumor site, a delivery system based on poly(lactic-co-glycolic acid) (PLGA) particles was used. Encapsulation was achieved by nanoemulsion, resulting in 59% PLGA particles containing PtNPs, and 12.5% PtNPs by weight. To improve the circulation time and specificity of the system, the PLGA particle surface was modified. Passive targeting with poly(ethylene glycol) (PEG) and active targeting with an antibody (anti-EGFR) were used, obtaining two different sets of particles, Pt–PLGA–PEG and Pt–PLGA–PEG–EGFR. To evaluate both sets of particles, cell studies were carried out against TNBC. Cell experiments demonstrated that Pt–PLGA–PEG–EGFR particles were more effective as a cancer treatment than Pt–PLGA–PEG particles, however, free PtNPs were more effective than the encapsulated PtNPs. This was likely due to the time needed for PtNPs to release from PLGA, however, the amount of Pt internalized in the cells was greater with the Pt–PLGA–PEG–EGFR particles. These results suggest that the Pt NPs encapsulated in PLGA modified with a combination of PEG and EGFR targeting will provide the most effective therapy for future in vivo experiments. In summary, this study lays the groundwork for future cancer treatments based on PtNPs delivered with targeted PLGA particles.

Graphical abstract: Poly(lactic-co-glycolic acid) encapsulated platinum nanoparticles for cancer treatment

Supplementary files

Article information

Article type
Paper
Submitted
07 dek 2021
Accepted
14 fev 2022
First published
16 fev 2022
This article is Open Access
Creative Commons BY license

Mater. Adv., 2022,3, 2858-2870

Poly(lactic-co-glycolic acid) encapsulated platinum nanoparticles for cancer treatment

A. López Ruiz, E. Villaseco Arribas and K. McEnnis, Mater. Adv., 2022, 3, 2858 DOI: 10.1039/D1MA01155C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements